Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Liuzhou
Clinical trial register · China

Clinical Trials in Liuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19282 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:17 UTC
19282
Studies in scope
all four open statuses
11840
Recruiting now
open to new participants
2032
Lead sponsors
across recruiting studies
Top sites
Beijing 5606 Shanghai 3892 Guangzhou 3359 Hangzhou 1833 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
First Affiliated Hospital of Guangxi Medical University7 Merck Sharp & Dohme LLC6 Bristol-Myers Squibb3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Suzhou Abogen Biosciences Co., Ltd.2 Rongrong Liu2 Novartis Pharmaceuticals2 Fourth Affiliated Hospital of Guangxi Medical University2 Sichuan Baili Pharmaceutical Co., Ltd.2 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 Shanghai Pharmaceuticals Holding Co., Ltd2 AstraZeneca2 Sun Yat-sen University2 Kind Pharmaceuticals LLC1 Nanjing Minova Pharmaceutical Co., Ltd.1 AbbVie1 Sinovac Life Sciences Co., Ltd.1 Advenchen Laboratories, LLC1 Beijing InnoCare Pharma Tech Co., Ltd.1 The Second Hospital of Anhui Medical University1 Peking University1 Oupushifang Pharmaceutical Technology Co., Ltd.1 Shanghai Bovax Biotechnology Co., Ltd.1 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1 Guangxi Medical University1 Show all 47
Site location
Beijing5606 Shanghai3892 Guangzhou3359 Hangzhou1833 Wuhan1342 Chengdu1310 Nanjing1216 Changsha1159 Chongqing1085 Fuzhou1041 Tianjin940 Zhengzhou926 Hefei909 Jinan794 Changchun642 Shenzhen585 Harbin549 Nanchang449 Nanning443 Xi'an443 Suzhou433 Shenyang406 Xiamen391 Shijiazhuang351 Lanzhou273 Show all 625
All 625 locations
Target enrolment
to

Trials with a site in Liuzhou

71 of 19282 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AstraZeneca
Phase 3
204
Beijing, Chifeng, Guangzhou, Hangzhou, Ha’erbin, Hefei, Liuzhou, Luoyang
2026-12-21
Not yet open
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Not applicable
260
Foshan, Guangzhou, Jiangyin, Kunming, Liuzhou, Nanjing, Shanghai, Sichuan
2026-11-15
Not yet open
SPH Sine Pharmaceutical Laboratories Co., Ltd.
Phase 2
150
Beijing, Chongqing, Shenzhen, Liuzhou, Xinxiang, Shiyan, Zhuzhou, Changchun
2026-10-20
Not yet open
CascadeDiagnose Prostate MRI
NCT07844304Prostate Cancer (Diagnosis)
First Affiliated Hospital of Guangxi Medical University
Observational
3,000
Guigang, Guilin, Liuzhou, Nanning, Wuzhou
2026-10-01
Not yet open
Federated Learning in Renal Tumor Model
NCT07841756Renal Tumors
First Affiliated Hospital of Guangxi Medical University
Observational
3,000
Guigang, Guilin, Liuzhou, Nanning, Wuzhou
2026-10-01
Recruiting
First Affiliated Hospital of Guangxi Medical University
Phase 3
352
Xiamen, Guangzhou, Baise City, Chongzuo, Guigang, Laibin, Liuzhou, Nanning
2026-09-24
Not yet open
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
NCT07764887Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
First Affiliated Hospital of Guangxi Medical University
Not applicable
536
Baise City, Beihai, Guigang, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2026-08-30
Recruiting
Sanofi
Phase 3
4,568
Huanggang, Jianli City, Jingzhou City, Jingxi, Liuzhou, Nanning, Tengzhou Town, Wuhan, Xiangyang City, Hubei Province
2026-08-22
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961Postpartum Depression (PPD)
Nanjing Minova Pharmaceutical Co., Ltd.
Phase 3
200
Hefei, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhaoqing, Liuzhou, Guiyang
2026-07-10
Recruiting
AstraZeneca
Phase 3
900
Binzhou, Changsha, Chengdu, Hangzhou, Jinan, Liaocheng, Liuzhou, Luoyang
2026-07-06
Not yet open
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Not yet open
ScinnoHub Pharmaceutical Co., Ltd.
Phase 2
30
Foshan, Guangzhou, Maoming, Liuzhou, Nanning, Haikou, Chengdu
2026-06-18
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Not yet open
Multi-Site Cortical Puncture for DOR
NCT07568639Diminished Ovarian Reserve (DOR)
First Affiliated Hospital of Guangxi Medical University
Not applicable
214
Xiamen, Guigang, Liuzhou, Nanning, Qinzhou
2026-04-30
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
126
Foshan, Gaozhou, Guangzhou, Huizhou, Zhaoqing, Liuzhou
2026-04-01
Recruiting
Rongrong Liu
Phase 2
78
Shenzhen, Baise City, Liuzhou, Yulin, Kunming, Naning
2026-02-01
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Recruiting
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Active, closed
Suzhou Abogen Biosciences Co., Ltd.
Phase 2
300
Liuzhou
2025-11-15
Recruiting
Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss
NCT07505667Sudden Hearing Loss, Sensorineural Hearing Loss
Guangdong Provincial People's Hospital
Not applicable
128
Guangzhou, Shenzhen, Zhongshan, Liuzhou, Ganzhou
2025-11-15
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Not yet open
Hai-Qiang Mai,MD,PhD
Phase 3
550
Foshan, Guangzhou, Zhangjiang, Liuzhou, Wuzhou
2025-08-01
Recruiting
A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography
NCT07133516Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, Cardiovascular Diseases (CVD), Echocardiography
First Hospital of China Medical University
Observational
1,600
Huainan, Fuzhou, Meizhou, Shantou, Shenzhen, Baise City, Guilin, Liuzhou
2025-07-22
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
141
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning
2025-06-13
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
NCT07614256Prostate Cancer (Diagnosis), Clinically Significant Prostate Cancer
Guangxi Medical University
Observational
3,000
Liuzhou
2025-05-30
Active, closed
Suzhou Abogen Biosciences Co., Ltd.
Phase 1
180
Liuzhou
2025-05-27
Recruiting
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Ma’anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
144
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou
2025-04-18
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
383
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang
2025-03-20
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
256
Hefei, Beijing, Chongqing, Foshan, Jiangmen, Liuzhou, Yulin, Cangzhou
2025-03-17
Recruiting
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
Rongrong Liu
Phase 2
396
Maoming, Liuzhou, Nanning, Yulin, Haikou
2024-10-01
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Oupushifang Pharmaceutical Technology Co., Ltd.
Phase 3
606
Hefei, Xuancheng, Lanzhou, Liuzhou, Nanning, Guiyang, Zunyi, Daqing
2024-06-15
Recruiting
Kind Pharmaceuticals LLC
Phase 2
64
Guangzhou, Maoming, Liuzhou, Nanning, Haikou
2024-05-27
Recruiting
Peking University
Not applicable
2,560
Sanming, Liuzhou
2024-05-20
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
NCT06780683Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
DrugUpadacitinib
Xiang Gao
Observational
174
Guangzhou, Meizhou, Shenzhen, Liuzhou, Nanning
2024-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
52
Hefei, Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Xiangyang
2023-09-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
120
Lu'an, Beijing, Fuzhou, Xiamen, Wuwei, Shenzhen, Liuzhou, Yulin
2023-09-14
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
254
Guangzhou, Liuzhou, Anyang, Luoyang, Shijiazhuang, Harbin, Wuhan, Nanjing
2023-09-08
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Recruiting
First Affiliated Hospital of Guangxi Medical University
Not applicable
190
Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2023-06-12
Active, closed
CRUSTAL Study in China
NCT05828186Coronary Artery Disease, Calcification
First Affiliated Hospital of Guangxi Medical University
Observational
200
Liuzhou, Yulin, Nanjing, Guilin, Guiping
2023-05-04
Active, closed
Clinical Trial of Mica
NCT05680415Latent Tuberculosis Infection
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 4
6,800
Liuzhou
2023-04-19
Active, closed
Bristol-Myers Squibb
Phase 2
189
Guangzhou, Foshan, Maoming Shi, Shenzhen Shi, Liuzhou, Nanning, Haikou, Kunming
2022-12-09
Recruiting
Fourth Affiliated Hospital of Guangxi Medical University
Not applicable
288
Baise City, Guilin, Liuzhou, Nanjing, Qinzhou, Wuzhou
2022-12-01
Active, closed
Bristol-Myers Squibb
Phase 2
94
Maoming, Shenzhen, Liuzhou, Nanning, Haikou, Kunming, Guangzhou
2022-10-17
Recruiting
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Active, closed
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Recruiting
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
NCT05735145Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy
DrugPaclitaxel
Fourth Affiliated Hospital of Guangxi Medical University
Phase 3
108
Liuzhou
2022-07-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,590
Liuzhou, Louxing District, Guang’an, Mianyang
2022-05-07
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha
2022-03-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Recruiting
Advenchen Laboratories, LLC
Phase 1/2
228
Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning
2021-10-26
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Recruiting
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3
8,000
Liuzhou
2020-04-28
Rows per page Showing 1–71 of 71
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-china/city/liuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,282 studies in total at the last sync on 15 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 71 of those studies with a site in Liuzhou.

How many clinical trials are recruiting in Liuzhou?

42 of the 71 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:17 UTC sync. A further 11 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Liuzhou), 71 studies
PhaseStudiesRecruitingShare
Phase 3291640.8%
Phase 2181125.4%
Not applicable10714.1%
Observational739.9%
Phase 1/2334.2%
Phase 2/3222.8%
Phase 1101.4%
Phase 4101.4%

Most active sponsors

Lead sponsors with the most studies (Liuzhou)
Lead sponsorStudiesRecruiting
First Affiliated Hospital of Guangxi Medical University72
Merck Sharp & Dohme LLC63
Bristol-Myers Squibb31
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.32
AstraZeneca21
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.21
Fourth Affiliated Hospital of Guangxi Medical University22
Novartis Pharmaceuticals21
Rongrong Liu22
Shanghai Pharmaceuticals Holding Co., Ltd22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.